- Home
- CIFRW vs VCEL Comparison
CIFRW vs VCEL Comparison
Compare CIFRW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFRW
- VCEL
- Stock Information
- Founded
- CIFRW 2020
- VCEL 1989
- Country
- CIFRW United States
- VCEL United States
- Employees
- CIFRW 43
- VCEL N/A
- Industry
- CIFRW Investment Bankers/Brokers/Service
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIFRW Finance
- VCEL Health Care
- Exchange
- CIFRW Nasdaq
- VCEL Nasdaq
- Market Cap
- CIFRW N/A
- VCEL 2.1B
- IPO Year
- CIFRW N/A
- VCEL 1997
- Fundamental
- Price
- CIFRW N/A
- VCEL $40.15
- Analyst Decision
- CIFRW
- VCEL Strong Buy
- Analyst Count
- CIFRW 0
- VCEL 8
- Target Price
- CIFRW N/A
- VCEL $62.00
- AVG Volume (30 Days)
- CIFRW 67.9K
- VCEL 430.8K
- Earning Date
- CIFRW 02-25-2025
- VCEL 07-31-2025
- Dividend Yield
- CIFRW N/A
- VCEL N/A
- EPS Growth
- CIFRW N/A
- VCEL 521.85
- EPS
- CIFRW N/A
- VCEL 0.05
- Revenue
- CIFRW $152,466,000.00
- VCEL $238,541,000.00
- Revenue This Year
- CIFRW N/A
- VCEL $23.03
- Revenue Next Year
- CIFRW N/A
- VCEL $24.52
- P/E Ratio
- CIFRW N/A
- VCEL $705.61
- Revenue Growth
- CIFRW 76.34
- VCEL 14.80
- 52 Week Low
- CIFRW $1.58
- VCEL $37.39
- 52 Week High
- CIFRW $1.69
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- CIFRW N/A
- VCEL 44.33
- Support Level
- CIFRW N/A
- VCEL $40.53
- Resistance Level
- CIFRW N/A
- VCEL $43.57
- Average True Range (ATR)
- CIFRW 0.00
- VCEL 1.62
- MACD
- CIFRW 0.00
- VCEL -0.16
- Stochastic Oscillator
- CIFRW 0.00
- VCEL 28.65
About CIFRW Cipher Mining Inc. Warrant
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.